| Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies. | |
| | |
MedLine Citation:
|
PMID: 22181051 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
ABSTRACT Objectives. Little is known about toxicity-related costs of monoclonal antibody treatments in metastatic colorectal cancer. We aimed to identify toxicities associated with bevacizumab, cetuximab and panitumumab and estimate the direct costs of these toxicities. Methods. Grade 3 and 4 toxicities were identified by a comprehensive literature search. Inpatient costs were estimated using ICD-9 codes and 2007 Medicare payments from the Healthcare Cost and Utilization Project database; costs were converted to 2010 dollars. Outpatient costs were estimated by applying 2010 Medicare reimbursement rates to resource use assumptions (based on in-depth clinical interviews). Results. Toxicities associated with bevacizumab included hypertension, arterial thrombosis, haemorrhage, gastrointestinal (GI) perforation, fistula and wound-healing complications; toxicities associated with cetuximab and panitumumab included skin rash, hypomagnesaemia and infusion reactions. The inpatient cost per event was highest for GI perforation (USD 32,443), followed by fistula (USD 29,062), arterial thrombosis (USD 20,346), and wound-healing complications (USD 13,240), while inpatient costs per event for hypomagnesaemia and skin rash were among the lowest. The cost per event of toxicities treated in the outpatient setting included USD 185 for skin rash up to USD 585 for wound-healing complications. Limitations. Treatment costs of toxicities for the outpatient setting were determined using assumptions validated by clinicians and unit costs were based on Medicare reimbursement rates, which are often lower than the reimbursement rates for commercial health insurance plans. Toxicities included were only grades 3 and 4 adverse events and might be limited by differences between clinical studies. Conclusions. Monoclonal antibodies have different toxicity profiles and the costs associated with managing these toxicities vary greatly. |
| | |
Authors:
|
Chakkarin Burudpakdee; Zhongyun Zhao; Julie Munakata; Sue Gao; Karen Trochlil; Beth Barber |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-19 |
Journal Detail:
|
Title: Journal of medical economics Volume: - ISSN: 1941-837X ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9892255 Medline TA: J Med Econ Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Candidaemia in a European Paediatric University Hospital: a 10-year observational study.
Next Document: Costs of Pregabalin or Gabapentin for Painful Diabetic Peripheral Neuropathy.